Last reviewed · How we verify
consolidation 5-fluorouracil
At a glance
| Generic name | consolidation 5-fluorouracil |
|---|---|
| Also known as | fluorouracil, 5-FU |
| Sponsor | Radiation Therapy Oncology Group |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer (PHASE2)
- Irinotecan Liposome Plus Capecitabine and Enronsubemab Combined With Short-course Radiotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cancer (PHASE2)
- Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors (PHASE2)
- Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery (PHASE3)
- Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014) (PHASE3)
- Efficacy and Safety of Conventional Neoadjuvant Therapy Versus Total Neoadjuvant Therapy in Older Patients With Locally Advanced Rectal Cancer (NA)
- Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015) (PHASE3)
- Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- consolidation 5-fluorouracil CI brief — competitive landscape report
- consolidation 5-fluorouracil updates RSS · CI watch RSS
- Radiation Therapy Oncology Group portfolio CI